Malignant Mesothelioma Mortality - United States, 1999-2015

Jacek M Mazurek, Girija Syamlal, John M Wood, Scott A Hendricks, Ainsley Weston, Jacek M Mazurek, Girija Syamlal, John M Wood, Scott A Hendricks, Ainsley Weston

Abstract

Malignant mesothelioma is a neoplasm associated with occupational and environmental inhalation exposure to asbestos* fibers and other elongate mineral particles (EMPs) (1-3). Patients have a median survival of approximately 1 year from the time of diagnosis (1). The latency period from first causative exposure to malignant mesothelioma development typically ranges from 20 to 40 years but can be as long as 71 years (2,3). Hazardous occupational exposures to asbestos fibers and other EMPs have occurred in a variety of industrial operations, including mining and milling, manufacturing, shipbuilding and repair, and construction (3). Current exposures to commercial asbestos in the United States occur predominantly during maintenance operations and remediation of older buildings containing asbestos (3,4). To update information on malignant mesothelioma mortality (5), CDC analyzed annual multiple cause-of-death records† for 1999-2015, the most recent years for which complete data are available. During 1999-2015, a total of 45,221 deaths with malignant mesothelioma mentioned on the death certificate as the underlying or contributing cause of death were reported in the United States, increasing from 2,479 deaths in 1999 to 2,597 in 2015 (in the same time period the age-adjusted death rates§ decreased from 13.96 per million in 1999 to 10.93 in 2015). Malignant mesothelioma deaths increased for persons aged ≥85 years, both sexes, persons of white, black, and Asian or Pacific Islander race, and all ethnic groups. Despite regulatory actions and the decline in use of asbestos the annual number of malignant mesothelioma deaths remains substantial. The continuing occurrence of malignant mesothelioma deaths underscores the need for maintaining measures to prevent exposure to asbestos fibers and other causative EMPs and for ongoing surveillance to monitor temporal trends.

Figures

FIGURE
FIGURE
Malignant mesothelioma annualized age-adjusted death rate per 1 million population, by state — United States, 1999–2015 * Age-adjusted death rates were calculated by applying age-specific death rates to the 2000 U.S standard population age distribution (https://wonder.cdc.gov/wonder/help/mcd.html#Age-Adjusted Rates). In two states (Maine and Washington), the age-adjusted death rate exceeded 20 per million per year. † Decedents aged ≥25 years for whom the International Classification of Diseases, 10th Revision codes C45.0 (mesothelioma of pleura), C45.1 (mesothelioma of peritoneum), C45.2 (mesothelioma of pericardium), C45.7 (mesothelioma of other sites), or C45.9 (mesothelioma, unspecified) were listed on death certificates were identified using CDC multiple cause-of-death data for 1999–2015.

References

    1. Lemen RA. Mesothelioma from asbestos exposures: epidemiologic patterns and impact in the United States. J Toxicol Environ Health B Crit Rev 2016;19:250–65. 10.1080/10937404.2016.1195323
    1. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34:718–21.
    1. National Institute for Occupational Safety and Health. Current intelligence bulletin 62. Asbestos fibers and other elongate mineral particles: state of the science and roadmap for research. Cincinnati, Ohio: US Department of Health and Human Services, CDC, National Institute for Occupational Safety and Health; 2011.
    1. Nicholson WJ, Perkel G, Selikoff IJ. Occupational exposure to asbestos: population at risk and projected mortality—1980–2030. Am J Ind Med 1982;3:259–311. 10.1002/ajim.4700030305
    1. Bang KM, Mazurek JM, Storey E, Attfield MD, Schleiff PL, Wassell JT. Malignant mesothelioma mortality—United States, 1999–2005. MMWR Morb Mortal Wkly Rep 2009;58:393–6.
    1. Martonik JF, Nash E, Grossman E. The history of OSHA’s asbestos rule makings and some distinctive approaches that they introduced for regulating occupational exposure to toxic substances. AIHAJ 2001;62:208–17. 10.1080/15298660108984624
    1. Carlin DJ, Larson TC, Pfau JC, et al. Current research and opportunities to address environmental asbestos exposures. Environ Health Perspect 2015;123:A194–7. 10.1289/ehp.1409662
    1. Gordon RE, Fitzgerald S, Millette J. Asbestos in commercial cosmetic talcum powder as a cause of mesothelioma in women. Int J Occup Environ Health 2014;20:318–32. 10.1179/2049396714Y.0000000081
    1. Lilienfeld DE, Mandel JS, Coin P, Schuman LM. Projection of asbestos related diseases in the United States, 1985–2009. I. Cancer. Br J Ind Med 1988;45:283–91.
    1. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004;159:107–12. 10.1093/aje/kwh025

Source: PubMed

3
Abonnieren